Morgan Stanley
RXRX icon

Morgan Stanley’s Recursion Pharmaceuticals RXRX Stock Holding History

Morgan Stanley’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.71M Sell
2,185,329
-3,472,249
-61% -$13.4M ﹤0.01% 3901
2025
Q4 		$23.1M Sell
5,657,578
-1,632,775
-22% -$8.09M ﹤0.01% 2794
2025
Q3 		$35.6M Buy
7,290,353
+1,600,741
+28% +$8.41M ﹤0.01% 2326
2025
Q2 		$28.8M Buy
5,689,612
+679,179
+14% +$3.34M ﹤0.01% 2452
2025
Q1 		$26.5M Buy
5,010,433
+2,149,906
+75% +$15.7M ﹤0.01% 2405
2024
Q4 		$19.3M Buy
2,860,527
+983,326
+52% +$6.61M ﹤0.01% 2782
2024
Q3 		$12.4M Buy
1,877,201
+108,889
+6% +$781K ﹤0.01% 3261
2024
Q2 		$13.3M Sell
1,768,312
-195,465
-10% -$1.7M ﹤0.01% 3089
2024
Q1 		$19.6M Sell
1,963,777
-3,188,021
-62% -$35.5M ﹤0.01% 2719
2023
Q4 		$50.8M Buy
5,151,798
+4,345,176
+539% +$31M ﹤0.01% 2433
2023
Q3 		$6.17M Buy
806,622
+416,393
+107% +$4.15M ﹤0.01% 3565
2023
Q2 		$2.92M Buy
390,229
+130,862
+50% +$916K ﹤0.01% 4174
2023
Q1 		$1.73M Sell
259,367
-73,804
-22% -$586K ﹤0.01% 4547
2022
Q4 		$2.57M Buy
333,171
+57,229
+21% +$561K ﹤0.01% 4297
2022
Q3 		$2.94M Buy
275,942
+54,238
+24% +$549K ﹤0.01% 4145
2022
Q2 		$1.8M Buy
221,704
+81,107
+58% +$543K ﹤0.01% 4615
2022
Q1 		$1.01M Buy
140,597
+25,096
+22% +$267K ﹤0.01% 4994
2021
Q4 		$1.98M Buy
115,501
+105,801
+1,091% +$1.99M ﹤0.01% 4593
2021
Q3 		$223K Buy
9,700
+8,564
+754% +$243K ﹤0.01% 5942
2021
Q2 		$41K Buy
+1,136
New +$33.6K ﹤0.01% 6749

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley's RXRX Position: Q1 2026 in Review

Morgan Stanley reduced its Recursion Pharmaceuticals (RXRX) stake by 61% in Q1 2026, selling an estimated $13.4M and leaving 2,185,329 shares worth $6.71M. The position accounts for ﹤0.01% of the portfolio, ranked #3901.

Morgan Stanley first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $50.8M in Q4 2023. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Morgan Stanley held 2,185,329 shares of Recursion Pharmaceuticals worth $6.71M as of Q1 2026.
  • Morgan Stanley sold 3,472,249 Recursion Pharmaceuticals shares in Q1 2026, an estimated $13.4M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3901 holding.
  • Morgan Stanley first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Morgan Stanley's Recursion Pharmaceuticals position peaked at $50.8M in Q4 2023.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.